iRadimed (IRMD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on iRadimed (IRMD) is Neutral.

The composite score behind that read is +0.00, weighing +0.17 of bullish evidence against -0.25 bearish.

iRadimed last closed at $87.45, +1.83% on the session.

Against the IVW growth benchmark the position is +1.03% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

3 graded predictions for IRMD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks iRadimed in the 15th percentile on valuation and the 83rd percentile on return on equity, where 100 is best.

iRadimed is classified under Health Care / Health Care Equipment & Supplies, with a market capitalisation of $1.10B.

StockMap tracks iRadimed as the 56th largest of the 140 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.

Across that group the current two-week reads are 122 Neutral, 16 Moderate Underperform and 2 Moderate Outperform.

On that composite iRadimed ranks 48th of 140 in the group, against a group median of -0.03.